Needham analyst Ami Fadia maintains $Jazz Pharmaceuticals (JAZZ.US)$ with a buy rating, and maintains the target price at $207.
According to TipRanks data, the analyst has a success rate of 52.1% and a total average return of 7.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Jazz Pharmaceuticals (JAZZ.US)$'s main analysts recently are as follows:
Jazz Pharmaceuticals has reported third-quarter revenue that aligned with expectations, alongside a significant non-GAAP net income surplus, even though outcomes were momentarily affected by variables impacting the Rylaze brand. Overall, the third-quarter results were deemed 'solid.' It's believed that Jazz is positioned enticingly, with a valuation reflecting 'highly depressed multiples,' while still promising mid-single digit revenue growth and high-single digit profit growth rates on an annual compound basis.
Jazz Pharmaceuticals' Q3 revenue outperformance was propelled by robust expansion in its principal growth contributors, Xywav and Epidiolex. Conversely, Rylaze experienced a temporary setback due to modifications in the treatment protocol.
The firm noted that Jazz Pharmaceuticals' total Q3 revenue exceeded expectations, aided by the performance of Xywav, Epidiolex, Defitelio, and Zepzelca.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Needham分析師Ami Fadia維持$爵士製藥 (JAZZ.US)$買入評級，維持目標價207美元。
根據TipRanks數據顯示，該分析師近一年總勝率為52.1%，總平均回報率為7.4%。
此外，綜合報道，$爵士製藥 (JAZZ.US)$近期主要分析師觀點如下：
爵士製藥報告顯示，第三季度營業收入符合預期，並且非通用會計淨利潤盈餘顯着，儘管結果受到影響Rylaze品牌的變數的瞬時影響。總體而言，第三季度的成果被認爲"穩健"。人們相信爵士製藥的定位很具吸引力，估值反映了"高度不景氣的倍數"，同時承諾以年複合基準實現中單位數營業收入增長和高單位數利潤增長率。
爵士製藥第三季度營收強勁增長的推動力來自其主要增長貢獻者Xywav和Epidiolex。相反，Rylaze因治療方案的修改經歷了暫時的挫折。
該公司指出，爵士製藥的第三季度總營收超出預期，得益於Xywav、Epidiolex、Defitelio和Zepzelca的表現。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
